# CVN058 Effect on Mismatch Negativity in Schizophrenics

> **NCT03669250** · PHASE1 · COMPLETED · sponsor: **Cerevance Alpha, Inc.** · enrollment: 22 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** CVN058
- **OTHER:** Placebo comparator

## Key facts

- **NCT ID:** NCT03669250
- **Lead sponsor:** Cerevance Alpha, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-09
- **Primary completion:** 2020-03-06
- **Final completion:** 2020-03-06
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2024-10-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03669250

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03669250, "CVN058 Effect on Mismatch Negativity in Schizophrenics". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03669250. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*